2238 Pro, Barbara - Thomas Jefferson University - Thomas Jefferson University
bxp022

Barbara Pro, MD

Contact Dr. Pro

925 Chestnut Street
Suite 420A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins’ Lymphoma in First Remission
  2. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma
  3. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
  4. Current management of peripheral t-cell lymphomas
  5. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  6. Kaposi sarcoma mimicking multiple cherry angiomata clinically and histologically in a patient with sezary syndrome: An unusual presentation
  7. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label, single arm, phase II trial
  8. Comparison of survival in patients with t cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease
  9. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study
  10. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins
  11. Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
  12. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
  13. The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: A retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)
  14. Paclitaxel, topotecan and rituximab: Long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
  15. 90Y-ibritumomab 09CE tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease
  16. Peripheral T-cell lymphomas: A review of current approaches and hopes for the future
  17. Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
  18. Racial differences in chronic lymphocytic leukemia: Digging deeper
  19. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
  20. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial
0